American Association for Cancer Research
Browse
ccr-23-1789_supplementary_table_s6_suppts6.xlsx (12.81 kB)

Supplementary Table S6 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer

Download (12.81 kB)
dataset
posted on 2024-04-01, 07:22 authored by Noah Earland, Nicholas P. Semenkovich, Ricardo J. Ramirez, Sophie P. Gerndt, Peter K. Harris, Zhuosheng Gu, Andrew I. Hearn, Matthew Inkman, Jeffrey J. Szymanski, Damion Whitfield, Benjamin M. Wahle, Zhongping Xu, Kevin Chen, Irfan Alahi, Gabris Ni, Andrew Chen, Wendy Winckler, Jin Zhang, Aadel A. Chaudhuri, Jose P. Zevallos

Supplemental Table S6. HPV (+) OPSCC de-escalation trial eligibility criteria

Funding

National Institute of Deafness and Other Communication Disorders

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

V Foundation for Cancer Research (VFCR)

National Center for Advancing Translational Sciences (NCATS)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

Our goal was to demonstrate that lymphatic drainage fluid (lymph) has improved sensitivity in quantifying postoperative minimal residual disease (MRD) in locally advanced human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) compared with plasma, and leverage this novel biofluid for patient risk stratification. We prospectively collected lymph samples from neck drains of 106 patients with HPV (+) OPSCC, along with 67 matched plasma samples, 24 hours after surgery. PCR and next-generation sequencing were used to quantify cancer-associated cell-free HPV (cf-HPV) and tumor-informed variants in lymph and plasma. Next, lymph cf-HPV and variants were compared with TNM stage, extranodal extension (ENE), and composite definitions of high-risk pathology. We then created a machine learning model, informed by lymph MRD and clinicopathologic features, to compare with progression-free survival (PFS). Postoperative lymph was enriched with cf-HPV compared with plasma (P < 0.0001) and correlated with pN2 stage (P = 0.003), ENE (P < 0.0001), and trial-defined pathologic risk criteria (mean AUC = 0.78). In addition, the lymph mutation number and variant allele frequency were higher in pN2 ENE (+) necks than in pN1 ENE (+) (P = 0.03, P = 0.02) or pN0-N1 ENE (−) (P = 0.04, P = 0.03, respectively). The lymph MRD-informed risk model demonstrated inferior PFS in high-risk patients (AUC = 0.96, P < 0.0001). Variant and cf-HPV quantification, performed in 24-hour postoperative lymph samples, reflects single- and multifeature high-risk pathologic criteria. Incorporating lymphatic MRD and clinicopathologic feature analysis can stratify PFS early after surgery in patients with HPV (+) head and neck cancer.See related commentary by Shannon and Iyer, p. 1223